Brief: AEON Biopharma Merges With Priveterra Acquisition To Become Publicly Listed

Aeon Biopharma

13/12/2022 12:33

Dec 13 (Reuters) - Priveterra Acquisition Corp  PMGM.O :
    * AEON BIOPHARMA TO BECOME PUBLICLY LISTED VIA MERGER WITH
PRIVETERRA ACQUISITION CORP.; ACCELERATING CLINICAL DEVELOPMENT
OF ABP-450 (PRABOTULINUMTOXINA) INJECTION TO TREAT DEBILITATING
MEDICAL CONDITIONS IN NEUROLOGY
    * PRIVETERRA ACQUISITION - ROBERT PALMISANO OF PRIVETERRA TO
BECOME CHAIRMAN OF BOARD OF DIRECTORS; COMBINED COMPANY TO BE
LED BY AEON CEO MARC FORTH
    * PRIVETERRA ACQUISITION  - TRANSACTION VALUES COMBINED CO
AT
POST-MONEY EQUITY VALUE OF $475.5M & IS EXPECTED TO PROVIDE
$276M IN GROSS CASH PROCEEDS
    * PRIVETERRA ACQUISITION - UPON CLOSING OF PROPOSED
TRANSACTION,
COMBINED CO TO OPERATE AS AEON BIOPHARMA, INC.
    * PRIVETERRA ACQUISITION CORP - UPON CLOSING OF PROPOSED
TRANSACTION, COMBINED COMPANY IS EXPECTED TO LIST ON NASDAQ
UNDER TICKER SYMBOL "AEON"

Source text for Eikon:  ID:nGNX1w9gMk 
Further company coverage:  PMGM.O 
 ((Reuters.Briefs@thomsonreuters.com;))